Systematic evolution of ligands by exponential enrichment

Last updated
A schematic of the major phases in a SELEX experiment. This cycle, may be repeated up to 20 times over a period lasting weeks, though some methods require far fewer cycles. SELEX schematic.png
A schematic of the major phases in a SELEX experiment. This cycle, may be repeated up to 20 times over a period lasting weeks, though some methods require far fewer cycles.
Structure of an RNA aptamer specific for biotin. The aptamer surface and backbone are shown in yellow. Biotin (spheres) fits snugly into a cavity of the RNA surface. Aptamer biotin.png
Structure of an RNA aptamer specific for biotin. The aptamer surface and backbone are shown in yellow. Biotin (spheres) fits snugly into a cavity of the RNA surface.

Systematic evolution of ligands by exponential enrichment (SELEX), also referred to as in vitro selection or in vitro evolution , is a combinatorial chemistry technique in molecular biology for producing oligonucleotides of either single-stranded DNA or RNA that specifically bind to a target ligand or ligands. These single-stranded DNA or RNA are commonly referred to as aptamers. [1] [2] [3] Although SELEX has emerged as the most commonly used name for the procedure, some researchers have referred to it as SAAB (selected and amplified binding site) and CASTing (cyclic amplification and selection of targets) [4] [5] SELEX was first introduced in 1990. In 2015, a special issue was published in the Journal of Molecular Evolution in the honor of quarter century of the discovery of SELEX. [6]

Contents

The process begins with the synthesis of a very large oligonucleotide library, consisting of randomly generated sequences of fixed length flanked by constant 5' and 3' ends. The constant ends serve as primers, while a small number of random regions are expected to bind specifically to the chosen target. For a randomly generated region of length n, the number of possible sequences in the library using conventional DNA or RNA is 4n (n positions with four possibilities (A,T,C,G) at each position). The sequences in the library are exposed to the target ligand - which may be a protein or a small organic compound - and those that do not bind the target are removed, usually by affinity chromatography or target capture on paramagnetic beads. [7] The bound sequences are eluted and amplified by PCR [2] [3] to prepare for subsequent rounds of selection in which the stringency of the elution conditions can be increased to identify the tightest-binding sequences. [2] A caution to consider in this method is that the selection of extremely high, sub-nanomolar binding affinity entities may not in fact improve specificity for the target molecule. [8] Off-target binding to related molecules could have significant clinical effects.

SELEX has been used to develop a number of aptamers that bind targets interesting for both clinical and research purposes. [9] Nucleotides with chemically modified sugars and bases have been incorporated into SELEX reactions to increase the chemical diversity at each base, expanding the possibilities for specific and sensitive binding, or increasing stability in serum or in vivo . [9] [10]

Procedure

Aptamers have emerged as a novel category in the field of bioreceptors due to their wide applications ranging from biosensing to therapeutics. Several variations of their screening process, called SELEX have been reported which can yield sequences with desired properties needed for their final use. [11]

Generating single stranded oligonucleotide library

The first step of SELEX involves the synthesis of fully or partially randomized oligonucleotide sequences of some length flanked by defined regions which allow PCR amplification of those randomized regions and, in the case of RNA SELEX, in vitro transcription of the randomized sequence. [2] [3] [12] While Ellington and Szostak demonstrated that chemical synthesis is capable of generating ~1015 unique sequences for oligonucleotide libraries in their 1990 paper on in vitro selection, [3] they found that amplification of these synthesized oligonucleotides led to significant loss of pool diversity due to PCR bias and defects in synthesized fragments. [3] The oligonucleotide pool is amplified and a sufficient amount of the initial library is added to the reaction so that there are numerous copies of each individual sequence to minimize the loss of potential binding sequences due to stochastic events. [3] Before the library is introduced to target for incubation and selective retention, the sequence library must be converted to single stranded oligonucleotides to achieve structural conformations with target binding properties. [2] [3]

Target incubation

Immediately prior to target introduction, the single stranded oligonucleotide library is often heated and cooled slowly to renature oligonucleotides into thermodynamically stable secondary and tertiary structures. [3] [7] Once prepared, the randomized library is incubated with immobilized target to allow oligonucleotide-target binding. There are several considerations for this target incubation step, including the target immobilization method and strategies for subsequent unbound oligonucleotide separation, incubation time and temperature, incubation buffer conditions, and target versus oligonucleotide concentrations. Examples of target immobilization methods include affinity chromatography columns, [3] nitrocellulose binding assay filters, [2] and paramagnetic beads. [7] Recently, SELEX reactions have been developed where the target is whole cells, which are expanded near complete confluence and incubated with the oligonucleotide library on culture plates. [13] Incubation buffer conditions are altered based on the intended target and desired function of the selected aptamer. For example, in the case of negatively charged small molecules and proteins, high salt buffers are used for charge screening to allow nucleotides to approach the target and increase the chance of a specific binding event. [3] Alternatively, if the desired aptamer function is in vivo protein or whole cell binding for potential therapeutic or diagnostic application, incubation buffer conditions similar to in vivo plasma salt concentrations and homeostatic temperatures are more likely to generate aptamers that can bind in vivo. Another consideration in incubation buffer conditions is non-specific competitors. If there is a high likelihood of non-specific oligonucleotide retention in the reaction conditions, non specific competitors, which are small molecules or polymers other than the SELEX library that have similar physical properties to the library oligonucleotides, can be used to occupy these non-specific binding sites. [13] Varying the relative concentration of target and oligonucleotides can also affect properties of the selected aptamers. If a good binding affinity for the selected aptamer is not a concern, then an excess of target can be used to increase the probability that at least some sequences will bind during incubation and be retained. However, this provides no selective pressure for high binding affinity, which requires the oligonucleotide library to be in excess so that there is competition between unique sequences for available specific binding sites. [2]

Binding sequence elution and amplification

Once the oligonucleotide library has been incubated with target for sufficient time, unbound oligonucleotides are washed away from immobilized target, often using the incubation buffer so that specifically bound oligonucleotides are retained. [3] With unbound sequences washed away, the specifically bound sequences are then eluted by creating denaturing conditions that promote oligonucleotide unfolding or loss of binding conformation including flowing in deionized water, [3] using denaturing solutions containing urea and EDTA, [13] [14] or by applying high heat and physical force. [7] Upon elution of bound sequences, the retained oligonucleotides are reverse-transcribed to DNA in the case of RNA or modified base selections, [2] [3] [13] or simply collected for amplification in the case of DNA SELEX. [15] These DNA templates from eluted sequences are then amplified via PCR and converted to single stranded DNA, RNA, or modified base oligonucleotides, which are used as the initial input for the next round of selection. [2] [3]

Obtaining ssDNA

One of the most critical steps in the SELEX procedure is obtaining single stranded DNA (ssDNA) after the PCR amplification step. This will serve as input for the next cycle so it is of vital importance that all the DNA is single stranded and as little as possible is lost. Because of the relative simplicity, one of the most used methods is using biotinylated reverse primers in the amplification step, after which the complementary strands can be bound to a resin followed by elution of the other strand with lye. Another method is asymmetric PCR, where the amplification step is performed with an excess of forward primer and very little reverse primer, which leads to the production of more of the desired strand. A drawback of this method is that the product should be purified from double stranded DNA (dsDNA) and other left-over material from the PCR reaction. Enzymatic degradation of the unwanted strand can be performed by tagging this strand using a phosphate-probed primer, as it is recognized by enzymes such as Lambda exonuclease. These enzymes then selectively degrade the phosphate tagged strand leaving the complementary strand intact. All of these methods recover approximately 50 to 70% of the DNA. For a detailed comparison refer to the article by Svobodová et al. where these, and other, methods are experimentally compared. [16] In classical SELEX, the process of randomized single stranded library generation, target incubation, and binding sequence elution and amplification described above are repeated until the vast majority of the retained pool consists of target binding sequences, [2] [3] though there are modifications and additions to the procedure that are often used, which are discussed below.

Negative or counter selection

In order to increase the specificity of aptamers selected by a given SELEX procedure, a negative selection, or counter selection, step can be added prior to or immediately following target incubation. To eliminate sequences with affinity for target immobilization matrix components from the pool, negative selection can be used where the library is incubated with target immobilization matrix components and unbound sequences are retained. [14] [17] [15] Negative selection can also be used to eliminate sequences that bind target-like molecules or cells by incubating the oligonucleotide library with small molecule target analogs, undesired cell types, or non-target proteins and retaining the unbound sequences. [13] [15] [18]

Tracking selection progression

To track the progress of a SELEX reaction, the number of target bound molecules, which is equivalent to the number of oligonucleotides eluted, can be compared to the estimated total input of oligonucleotides following elution at each round. [3] [19] The number of eluted oligonucleotides can be estimated through elution concentration estimations via 260 nm wavelength absorbance [19] or fluorescent labeling of oligonucleotides. [7] As the SELEX reaction approaches completion, the fraction of the oligonucleotide library that binds target approaches 100%, such that the number of eluted molecules approaches the total oligonucleotide input estimate, but may converge at a lower number. [3]

Caveats and considerations

Some SELEX reactions can generate probes that are dependent on primer binding regions for secondary structure formation. [7] There are aptamer applications for which a short sequence, and thus primer truncation, is desirable. [20] An advancement on the original method allows an RNA library to omit the constant primer regions, which can be difficult to remove after the selection process because they stabilize secondary structures that are unstable when formed by the random region alone. [21]

Chemically modified nucleotides

Recently, SELEX has expanded to include the use of chemically modified nucleotides. These chemically modified oligonucleotides offer many potential advantages for selected aptamers including greater stability and nuclease resistance, enhanced binding for select targets, expanded physical properties - like increased hydrophobicity, and more diverse structural conformations. [9] [10] [22]

The genetic alphabet, and thus possible aptamers, is also expanded using unnatural base pairs [23] [24] the use of these unnatural base pairs was applied to SELEX and high affinity DNA aptamers were generated. [25]

SELEX variants and alternative aptamer selection methods

FRELEX was developed in 2016 by NeoVentures Biotechnology Inc to allow the selection of aptamers without immobilizing the target or the oligonucleotide library. [26] Immobilization is a necessary component of SELEX; however, it has the potential to inhibit key epitopes, and thus weaken the likelihood of successful binding, particularly when working with small molecules. [27] [28] FRELEX follows a similar overall methodology to SELEX; however, instead of immobilizing the target, the researcher introduces a series of random and blocker oligonucleotides to an immobilization field before introduction to the target. [26] This allows the researcher to better target small molecules that may be lost during partitioning. [26] It also can be used in some circumstances to select an aptamer library without knowing the target. [29]

Most modern aptamer selection methods strive to improve the conventional SELEX aptamer search method. [30] Despite the publication of various methods aimed at increasing the affinity and specificity of aptamers, [31] [32] [33] experimental approaches face limitations in the number and variety of sequences that can be examined and selected. Library capacity for SELEX experiments is practically limited to 1015 candidates, whereas, assuming there is a 4-monomeric repertoire from which pools can be created, there are ~1.6 × 1060 unique sequences in sequence space limited to a 100-residue matrix, which is clearly beyond experimental capabilities. [34] The library of oligonucleotides must be extremely diverse and not contain linear, incapable of providing a stable spatial arrangement, and double-stranded structures; due to these limitations, oligonucleotide libraries can cover the diversity of only ~106 sequences. [35] This means that existing aptamers may not fully cover the diversity of target molecules or may not have optimal properties due to limitations of the underlying method. To yield the best possible aptamers one must maximize the effectiveness of the discovery process and the library itself.

RNA and DNA secondary structure prediction by dynamic programming algorithms such as RNAfold (ViennaRNA) [36] and by machine learning models such as SPOT-RNA, [37] MXfold2 [38] provides the opportunity to assess the ability of sequences in the primary library to fold into complex structures, allowing for the selection of only the most promising sequences from the entire pool. However, these algorithms are low-performance, making them poorly suited for this task. For this reason, algorithms like Ufold from the University of California [39] and AliNA from Nanobiorobots Inc. [40] have been developed, which demonstrate a significant increase in computational speed due to their faster architecture, and can be applied for preliminary in silico analysis of these libraries.

Prior targets

The technique has been used to evolve aptamers of extremely high binding affinity to a variety of target ligands, including small molecules such as ATP [41] and adenosine [12] [42] and proteins such as prions [43] and vascular endothelial growth factor (VEGF). [44] Moreover, SELEX has been used to select high-affinity aptamers for complex targets such as tumor cells, [45] [46] tumor exosomes, [47] [48] or tumor tissue. [49] Clinical uses of the technique are suggested by aptamers that bind tumor markers, [50] GFP-related fluorophores, [51] and a VEGF-binding aptamer trade-named Macugen has been approved by the FDA for treatment of macular degeneration. [44] [52] Additionally, SELEX has been utilized to obtain highly specific catalytic DNA or DNAzymes. Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme (lead-specific), [53] the CA1-3 DNAzymes (copper-specific), [54] the 39E DNAzyme (uranyl-specific) [55] and the NaA43 DNAzyme (sodium-specific). [56]

These developed aptamers have seen diverse application in therapies for macular degeneration [52] and various research applications including biosensors, [20] fluorescent labeling of proteins [57] and cells, [58] and selective enzyme inhibition. [59]

See also

Related Research Articles

Oligonucleotides are short DNA or RNA molecules, oligomers, that have a wide range of applications in genetic testing, research, and forensics. Commonly made in the laboratory by solid-phase chemical synthesis, these small fragments of nucleic acids can be manufactured as single-stranded molecules with any user-specified sequence, and so are vital for artificial gene synthesis, polymerase chain reaction (PCR), DNA sequencing, molecular cloning and as molecular probes. In nature, oligonucleotides are usually found as small RNA molecules that function in the regulation of gene expression, or are degradation intermediates derived from the breakdown of larger nucleic acid molecules.

<span class="mw-page-title-main">Blot (biology)</span>

A blot, in molecular biology and genetics, is a method of transferring proteins, DNA or RNA onto a carrier. In many instances, this is done after a gel electrophoresis, transferring the molecules from the gel onto the blotting membrane, and other times adding the samples directly onto the membrane. After the blotting, the transferred proteins, DNA or RNA are then visualized by colorant staining, autoradiographic visualization of radiolabelled molecules, or specific labelling of some proteins or nucleic acids. The latter is done with antibodies or hybridization probes that bind only to some molecules of the blot and have an enzyme joined to them. After proper washing, this enzymatic activity is visualized by incubation with proper reactive, rendering either a colored deposit on the blot or a chemiluminescent reaction which is registered by photographic film.

<span class="mw-page-title-main">Phage display</span> Biological technique to evolve proteins using bacteriophages

Phage display is a laboratory technique for the study of protein–protein, protein–peptide, and protein–DNA interactions that uses bacteriophages to connect proteins with the genetic information that encodes them. In this technique, a gene encoding a protein of interest is inserted into a phage coat protein gene, causing the phage to "display" the protein on its outside while containing the gene for the protein on its inside, resulting in a connection between genotype and phenotype. The proteins that the phages are displaying can then be screened against other proteins, peptides or DNA sequences, in order to detect interaction between the displayed protein and those of other molecules. In this way, large libraries of proteins can be screened and amplified in a process called in vitro selection, which is analogous to natural selection.

Deoxyribozymes, also called DNA enzymes, DNAzymes, or catalytic DNA, are DNA oligonucleotides that are capable of performing a specific chemical reaction, often but not always catalytic. This is similar to the action of other biological enzymes, such as proteins or ribozymes . However, in contrast to the abundance of protein enzymes in biological systems and the discovery of biological ribozymes in the 1980s, there is only little evidence for naturally occurring deoxyribozymes. Deoxyribozymes should not be confused with DNA aptamers which are oligonucleotides that selectively bind a target ligand, but do not catalyze a subsequent chemical reaction.

Ribosome display is a technique used to perform in vitro protein evolution to create proteins that can bind to a desired ligand. The process results in translated proteins that are associated with their mRNA progenitor which is used, as a complex, to bind to an immobilized ligand in a selection step. The mRNA-protein hybrids that bind well are then reverse transcribed to cDNA and their sequence amplified via PCR. The result is a nucleotide sequence that can be used to create tightly binding proteins.

<span class="mw-page-title-main">Aptamer</span> Oligonucleotide or peptide molecules that bind specific targets

Aptamers are short sequences of artificial DNA, RNA, XNA, or peptide that bind a specific target molecule, or family of target molecules. They exhibit a range of affinities, with variable levels of off-target binding and are sometimes classified as chemical antibodies. Aptamers and antibodies can be used in many of the same applications, but the nucleic acid-based structure of aptamers, which are mostly oligonucleotides, is very different from the amino acid-based structure of antibodies, which are proteins. This difference can make aptamers a better choice than antibodies for some purposes.

<i>In situ</i> hybridization Laboratory technique to localize nucleic acids

In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand to localize a specific DNA or RNA sequence in a portion or section of tissue or if the tissue is small enough, in the entire tissue, in cells, and in circulating tumor cells (CTCs). This is distinct from immunohistochemistry, which usually localizes proteins in tissue sections.

<span class="mw-page-title-main">Electrophoretic mobility shift assay</span>

An electrophoretic mobility shift assay (EMSA) or mobility shift electrophoresis, also referred as a gel shift assay, gel mobility shift assay, band shift assay, or gel retardation assay, is a common affinity electrophoresis technique used to study protein–DNA or protein–RNA interactions. This procedure can determine if a protein or mixture of proteins is capable of binding to a given DNA or RNA sequence, and can sometimes indicate if more than one protein molecule is involved in the binding complex. Gel shift assays are often performed in vitro concurrently with DNase footprinting, primer extension, and promoter-probe experiments when studying transcription initiation, DNA gang replication, DNA repair or RNA processing and maturation, as well as pre-mRNA splicing. Although precursors can be found in earlier literature, most current assays are based on methods described by Garner and Revzin and Fried and Crothers.

Threose nucleic acid (TNA) is an artificial genetic polymer in which the natural five-carbon ribose sugar found in RNA has been replaced by an unnatural four-carbon threose sugar. Invented by Albert Eschenmoser as part of his quest to explore the chemical etiology of RNA, TNA has become an important synthetic genetic polymer (XNA) due to its ability to efficiently base pair with complementary sequences of DNA and RNA. The main difference between TNA and DNA/RNA is their backbones. DNA and RNA have their phosphate backbones attached to the 5' carbon of the deoxyribose or ribose sugar ring, respectively. TNA, on the other hand, has it's phosphate backbone directly attached to the 3' carbon in the ring, since it does not have a 5' carbon. This modified backbone makes TNA, unlike DNA and RNA, completely refractory to nuclease digestion, making it a promising nucleic acid analog for therapeutic and diagnostic applications.

In biology, a branched DNA assay is a signal amplification assay that is used to detect nucleic acid molecules.

Therapeutic gene modulation refers to the practice of altering the expression of a gene at one of various stages, with a view to alleviate some form of ailment. It differs from gene therapy in that gene modulation seeks to alter the expression of an endogenous gene whereas gene therapy concerns the introduction of a gene whose product aids the recipient directly.

mRNA display

mRNA display is a display technique used for in vitro protein, and/or peptide evolution to create molecules that can bind to a desired target. The process results in translated peptides or proteins that are associated with their mRNA progenitor via a puromycin linkage. The complex then binds to an immobilized target in a selection step. The mRNA-protein fusions that bind well are then reverse transcribed to cDNA and their sequence amplified via a polymerase chain reaction. The result is a nucleotide sequence that encodes a peptide with high affinity for the molecule of interest.

Zinc finger protein chimera are chimeric proteins composed of a DNA-binding zinc finger protein domain and another domain through which the protein exerts its effect. The effector domain may be a transcriptional activator (A) or repressor (R), a methylation domain (M) or a nuclease (N).

DNA-encoded chemical libraries (DECL) is a technology for the synthesis and screening on an unprecedented scale of collections of small molecule compounds. DECL is used in medicinal chemistry to bridge the fields of combinatorial chemistry and molecular biology. The aim of DECL technology is to accelerate the drug discovery process and in particular early phase discovery activities such as target validation and hit identification.

<small>L</small>-Ribonucleic acid aptamer RNA-like molecule

An L-ribonucleic acid aptamer is an RNA-like molecule built from L-ribose units. It is an artificial oligonucleotide named for being a mirror image of natural oligonucleotides. L-RNA aptamers are a form of aptamers. Due to their L-nucleotides, they are highly resistant to degradation by nucleases. L-RNA aptamers are considered potential drugs and are currently being tested in clinical trials.

<span class="mw-page-title-main">Spinach aptamer</span>

The need for fluorescently tracking RNA rose as its roles in complex cellular functions has grown to not only include mRNA, rRNA, and tRNA, but also RNAi, siRNA, snoRNA, and lncRNA, among others. Spinach is a synthetically derived RNA aptamer born out of the need for a way of studying the role of RNAs at the cellular level. This aptamer was created using Systematic Evolution for Ligands by EXponential enrichment, or SELEX, which is also known as in vitro evolution.

<span class="mw-page-title-main">Optimer ligand</span>

Optimer ligands are short synthetic oligonucleotide molecules composed of DNA or RNA that bind to a specific target molecule. They are engineered to bind their target molecules with affinity typically in the low nanomolar range. Optimers can be used as antibody mimetics in a range of applications, and have been optimized to increase their stability, reduce their molecular weight, and offer increased scalability and consistency in manufacture compared to standard aptamer molecules.

Selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq) is a technique developed for the rapid identification of DNA binding specificities and affinities of full length monomeric and dimeric transcription factors in a fast and semi-high-throughput fashion.

<span class="mw-page-title-main">Electrochemical aptamer-based biosensors</span>

Aptamers, single-stranded RNA and DNA sequences, bind to an analyte and change their conformation. They function as nucleic acids selectively binding molecules such as proteins, bacteria cells, metal ions, etc. Aptamers can be developed to have precise specificity to bind to a desired target. Aptamers change conformation upon binding, altering the electrochemical properties which can be measured. The Systematic Evolution of Ligands by Exponential Enrichment (SELEX) process generates aptamers. Electrochemical aptamer-based (E-AB) biosensors is a device that takes advantage of the electrochemical and biological properties of aptamers to take real time, in vivo measurements.

RNA therapeutics are a new class of medications based on ribonucleic acid (RNA). Research has been working on clinical use since the 1990s, with significant success in cancer therapy in the early 2010s. In 2020 and 2021, mRNA vaccines have been developed globally for use in combating the coronavirus disease. The Pfizer–BioNTech COVID-19 vaccine was the first mRNA vaccine approved by a medicines regulator, followed by the Moderna COVID-19 vaccine, and others.

References

  1. ↑ Hak-Hagir A (1978). "[The Hak-Hagir skin conduit]". Zeitschrift für Urologie und Nephrologie. 71 (9): 639–642. PMID   362762.
  2. 1 2 3 4 5 6 7 8 9 10 Tuerk C, Gold L (August 1990). "Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase". Science. 249 (4968): 505–10. Bibcode:1990Sci...249..505T. doi:10.1126/science.2200121. PMID   2200121.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Ellington AD, Szostak JW (August 1990). "In vitro selection of RNA molecules that bind specific ligands". Nature. 346 (6287): 818–22. Bibcode:1990Natur.346..818E. doi:10.1038/346818a0. PMID   1697402. S2CID   4273647.
  4. ↑ Blackwell TK, Weintraub H (November 1990). "Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection". Science. 250 (4984): 1104–10. Bibcode:1990Sci...250.1104B. doi:10.1126/science.2174572. PMID   2174572. S2CID   1995608.
  5. ↑ Wright WE, Binder M, Funk W (August 1991). "Cyclic amplification and selection of targets (CASTing) for the myogenin consensus binding site". Molecular and Cellular Biology. 11 (8): 4104–10. doi:10.1128/mcb.11.8.4104. PMC   361222 . PMID   1649388.
  6. ↑ Gold L (December 2015). "SELEX: How It Happened and Where It will Go". Journal of Molecular Evolution. 81 (5–6): 140–143. Bibcode:2015JMolE..81..140G. doi:10.1007/s00239-015-9705-9. PMC   4661202 . PMID   26480964.
  7. 1 2 3 4 5 6 Stoltenburg R, Schubert T, Strehlitz B (2015-07-29). "In vitro Selection and Interaction Studies of a DNA Aptamer Targeting Protein A". PLOS ONE. 10 (7): e0134403. Bibcode:2015PLoSO..1034403S. doi: 10.1371/journal.pone.0134403 . PMC   4519192 . PMID   26221730.
  8. ↑ Carothers JM, Oestreich SC, Szostak JW (June 2006). "Aptamers selected for higher-affinity binding are not more specific for the target ligand". Journal of the American Chemical Society. 128 (24): 7929–37. doi:10.1021/ja060952q. PMC   4287982 . PMID   16771507.
  9. 1 2 3 Wu YX, Kwon YJ (August 2016). "Aptamers: The "evolution" of SELEX". Methods. 106: 21–8. doi:10.1016/j.ymeth.2016.04.020. PMID   27109056.
  10. 1 2 Keefe AD, Cload ST (August 2008). "SELEX with modified nucleotides". Current Opinion in Chemical Biology. 12 (4): 448–56. doi:10.1016/j.cbpa.2008.06.028. PMID   18644461.
  11. ↑ Shorie M, Kaur H (October 2018). "Microtitre Plate Based Cell-SELEX Method". Bio-Protocol. 8 (20): e3051. doi:10.21769/BioProtoc.3051. PMC   8342047 . PMID   34532522.
  12. 1 2 Huizenga DE, Szostak JW (January 1995). "A DNA aptamer that binds adenosine and ATP". Biochemistry. 34 (2): 656–65. doi:10.1021/bi00002a033. PMID   7819261.
  13. 1 2 3 4 5 Iwagawa T, Ohuchi SP, Watanabe S, Nakamura Y (January 2012). "Selection of RNA aptamers against mouse embryonic stem cells". Biochimie. 94 (1): 250–7. doi:10.1016/j.biochi.2011.10.017. PMID   22085640.
  14. 1 2 Vater A, Jarosch F, Buchner K, Klussmann S (November 2003). "Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX". Nucleic Acids Research. 31 (21): 130e–130. doi:10.1093/nar/gng130. PMC   275487 . PMID   14576330.
  15. 1 2 3 Blank M, Weinschenk T, Priemer M, Schluesener H (May 2001). "Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen". The Journal of Biological Chemistry. 276 (19): 16464–8. doi: 10.1074/jbc.M100347200 . PMID   11279054. S2CID   39002909.
  16. ↑ Svobodová M, Pinto A, Nadal P, O' Sullivan CK (August 2012). "Comparison of different methods for generation of single-stranded DNA for SELEX processes". Analytical and Bioanalytical Chemistry. 404 (3): 835–42. doi:10.1007/s00216-012-6183-4. PMID   22733247. S2CID   206910212.
  17. ↑ Stoltenburg R, Reinemann C, Strehlitz B (October 2007). "SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands". Biomolecular Engineering. 24 (4): 381–403. doi:10.1016/j.bioeng.2007.06.001. PMID   17627883.
  18. ↑ Haller AA, Sarnow P (August 1997). "In vitro selection of a 7-methyl-guanosine binding RNA that inhibits translation of capped mRNA molecules". Proceedings of the National Academy of Sciences of the United States of America. 94 (16): 8521–6. Bibcode:1997PNAS...94.8521H. doi: 10.1073/pnas.94.16.8521 . PMC   22984 . PMID   9238009.
  19. 1 2 Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W (June 2010). "Development of DNA aptamers using Cell-SELEX". Nature Protocols. 5 (6): 1169–85. doi:10.1038/nprot.2010.66. PMID   20539292. S2CID   4953042.
  20. 1 2 Lubin AA, Hunt BV, White RJ, Plaxco KW (March 2009). "Effects of probe length, probe geometry, and redox-tag placement on the performance of the electrochemical E-DNA sensor". Analytical Chemistry. 81 (6): 2150–8. doi:10.1021/ac802317k. PMID   19215066.
  21. ↑ Jarosch F, Buchner K, Klussmann S (July 2006). "In vitro selection using a dual RNA library that allows primerless selection". Nucleic Acids Research. 34 (12): e86. doi:10.1093/nar/gkl463. PMC   1524915 . PMID   16855281.
  22. ↑ Pinheiro VB, Taylor AI, Cozens C, Abramov M, Renders M, Zhang S, Chaput JC, Wengel J, Peak-Chew SY, McLaughlin SH, Herdewijn P, Holliger P (April 2012). "Synthetic genetic polymers capable of heredity and evolution". Science. 336 (6079): 341–4. Bibcode:2012Sci...336..341P. doi:10.1126/science.1217622. PMC   3362463 . PMID   22517858.
  23. ↑ Kimoto M, Kawai R, Mitsui T, Yokoyama S, Hirao I (February 2009). "An unnatural base pair system for efficient PCR amplification and functionalization of DNA molecules". Nucleic Acids Research. 37 (2): e14. doi:10.1093/nar/gkn956. PMC   2632903 . PMID   19073696.
  24. ↑ Yamashige R, Kimoto M, Takezawa Y, Sato A, Mitsui T, Yokoyama S, Hirao I (March 2012). "Highly specific unnatural base pair systems as a third base pair for PCR amplification". Nucleic Acids Research. 40 (6): 2793–806. doi:10.1093/nar/gkr1068. PMC   3315302 . PMID   22121213.
  25. ↑ Kimoto M, Yamashige R, Matsunaga K, Yokoyama S, Hirao I (May 2013). "Generation of high-affinity DNA aptamers using an expanded genetic alphabet". Nature Biotechnology. 31 (5): 453–7. doi:10.1038/nbt.2556. PMID   23563318. S2CID   23329867.
  26. 1 2 3 10415034,Penner, Gregory&CA,"United States Patent: 10415034 - Method for the selection of aptamers for unbound targets",issued September 17, 2019
  27. ↑ Kohlberger M, Gadermaier G (August 2021). "SELEX: Critical factors and optimization strategies for successful aptamer selection". Biotechnology and Applied Biochemistry. 69 (5): 1771–1792. doi:10.1002/bab.2244. PMC   9788027 . PMID   34427974. S2CID   237280042.
  28. ↑ Klapak D, Broadfoot S, Penner G, Singh A, Inapuri E (2018-10-11). "Development of novel aptamers for low-density lipoprotein particle quantification". PLOS ONE. 13 (10): e0205460. Bibcode:2018PLoSO..1305460K. doi: 10.1371/journal.pone.0205460 . PMC   6181373 . PMID   30307996.
  29. ↑ Lecocq S, Spinella K, Dubois B, Lista S, Hampel H, Penner G (2018-01-05). de Franciscis V (ed.). "Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice". PLOS ONE. 13 (1): e0190212. Bibcode:2018PLoSO..1390212L. doi: 10.1371/journal.pone.0190212 . PMC   5755763 . PMID   29304088.
  30. ↑ Tuerk C, Gold L (August 1990). "Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase". Science. 249 (4968): 505–510. Bibcode:1990Sci...249..505T. doi:10.1126/science.2200121. PMID   2200121.
  31. ↑ Nagano M, Toda T, Makino K, Miki H, Sugizaki Y, Tomizawa H, et al. (December 2022). "Discovery of a Highly Specific Anti-methotrexate (MTX) DNA Aptamer for Antibody-Independent MTX Detection". Analytical Chemistry. 94 (49): 17255–17262. doi:10.1021/acs.analchem.2c04182. PMID   36449359. S2CID   254095717.
  32. ↑ Gotrik MR, Feagin TA, Csordas AT, Nakamoto MA, Soh HT (September 2016). "Advancements in Aptamer Discovery Technologies". Accounts of Chemical Research. 49 (9): 1903–1910. doi:10.1021/acs.accounts.6b00283. PMID   27526193.
  33. ↑ Wang J, Yu J, Yang Q, McDermott J, Scott A, Vukovich M, et al. (January 2017). "Multiparameter Particle Display (MPPD): A Quantitative Screening Method for the Discovery of Highly Specific Aptamers". Angewandte Chemie. 56 (3): 744–747. doi:10.1002/anie.201608880. PMC   5225111 . PMID   27933702.
  34. ↑ Hall B, Micheletti JM, Satya P, Ogle K, Pollard J, Ellington AD (October 2009). "Design, synthesis, and amplification of DNA pools for in vitro selection". Current Protocols in Molecular Biology. Chapter 24 (1): Unit 24.2. doi:10.1002/0471142727.mb2402s88. hdl: 2027.42/143624 . PMID   19816932. S2CID   38063074.
  35. ↑ Kosuri S, Church GM (May 2014). "Large-scale de novo DNA synthesis: technologies and applications". Nature Methods. 11 (5): 499–507. doi:10.1038/nmeth.2918. PMC   7098426 . PMID   24781323.
  36. ↑ "ViennaRNA Web Services". rna.tbi.univie.ac.at. Retrieved 2024-02-14.
  37. ↑ Singh J, Hanson J, Paliwal K, Zhou Y (November 2019). "RNA secondary structure prediction using an ensemble of two-dimensional deep neural networks and transfer learning". Nature Communications. 10 (1): 5407. Bibcode:2019NatCo..10.5407S. doi:10.1038/s41467-019-13395-9. PMC   6881452 . PMID   31776342.
  38. ↑ Sato K, Akiyama M, Sakakibara Y (February 2021). "RNA secondary structure prediction using deep learning with thermodynamic integration". Nature Communications. 12 (1): 941. Bibcode:2021NatCo..12..941S. doi:10.1038/s41467-021-21194-4. PMC   7878809 . PMID   33574226.
  39. ↑ Fu L, Cao Y, Wu J, Peng Q, Nie Q, Xie X (February 2022). "UFold: fast and accurate RNA secondary structure prediction with deep learning" (PDF). Nucleic Acids Research. Bioinformatics. 50 (3): e14. doi:10.1101/2020.08.17.254896. PMID   34792173.
  40. ↑ Nasaev SS, Mukanov AR, Kuznetsov II, Veselovsky AV (December 2023). "AliNA - a deep learning program for RNA secondary structure prediction". Molecular Informatics. 42 (12): e202300113. doi:10.1002/minf.202300113. PMID   37710142. S2CID   261885112.
  41. ↑ Dieckmann T, Suzuki E, Nakamura GK, Feigon J (July 1996). "Solution structure of an ATP-binding RNA aptamer reveals a novel fold". RNA. 2 (7): 628–40. PMC   1369402 . PMID   8756406.
  42. ↑ Burke DH, Gold L (May 1997). "RNA aptamers to the adenosine moiety of S-adenosyl methionine: structural inferences from variations on a theme and the reproducibility of SELEX". Nucleic Acids Research. 25 (10): 2020–4. doi:10.1093/nar/25.10.2020. PMC   146680 . PMID   9115371.
  43. ↑ Mercey R, Lantier I, Maurel MC, Grosclaude J, Lantier F, Marc D (November 2006). "Fast, reversible interaction of prion protein with RNA aptamers containing specific sequence patterns". Archives of Virology. 151 (11): 2197–214. doi:10.1007/s00705-006-0790-3. PMID   16799875. S2CID   32195593.
  44. 1 2 Ulrich H, Trujillo CA, Nery AA, Alves JM, Majumder P, Resende RR, Martins AH (September 2006). "DNA and RNA aptamers: from tools for basic research towards therapeutic applications". Combinatorial Chemistry & High Throughput Screening. 9 (8): 619–32. doi:10.2174/138620706778249695. PMID   17017882.
  45. ↑ Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L (December 2003). "A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment". Proceedings of the National Academy of Sciences of the United States of America. 100 (26): 15416–21. Bibcode:2003PNAS..10015416D. doi: 10.1073/pnas.2136683100 . PMC   307582 . PMID   14676325.
  46. ↑ Mayer G, Ahmed MS, Dolf A, Endl E, Knolle PA, Famulok M (December 2010). "Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures". Nature Protocols. 5 (12): 1993–2004. doi:10.1038/nprot.2010.163. PMID   21127492. S2CID   4984082.
  47. ↑ Domenyuk V, Zhong Z, Stark A, Xiao N, O'Neill HA, Wei X, et al. (February 2017). "Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach". Scientific Reports. 7 (1): 42741. Bibcode:2017NatSR...742741D. doi:10.1038/srep42741. PMC   5316983 . PMID   28218293.
  48. ↑ Hornung T, O'Neill HA, Logie SC, Fowler KM, Duncan JE, Rosenow M, et al. (May 2020). "ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes". Nucleic Acids Research. 48 (8): 4013–4027. doi:10.1093/nar/gkaa034. PMC   7192620 . PMID   31989173.
  49. ↑ Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, et al. (March 2018). "Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes". Nature Communications. 9 (1): 1219. Bibcode:2018NatCo...9.1219D. doi:10.1038/s41467-018-03631-z. PMC   5865185 . PMID   29572535.
  50. ↑ Ferreira CS, Matthews CS, Missailidis S (2006). "DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers". Tumour Biology. 27 (6): 289–301. doi:10.1159/000096085. PMID   17033199. S2CID   41664944.
  51. ↑ Paige JS, Wu KY, Jaffrey SR (July 2011). "RNA mimics of green fluorescent protein". Science. 333 (6042): 642–6. Bibcode:2011Sci...333..642P. doi:10.1126/science.1207339. PMC   3314379 . PMID   21798953.
  52. 1 2 Vavvas D, D'Amico DJ (September 2006). "Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice". Ophthalmology Clinics of North America. 19 (3): 353–60. doi:10.1016/j.ohc.2006.05.008 (inactive 31 January 2024). PMID   16935210.{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link)
  53. ↑ Breaker RR, Joyce GF (December 1994). "A DNA enzyme that cleaves RNA". Chemistry & Biology. 1 (4): 223–9. doi:10.1016/1074-5521(94)90014-0. PMID   9383394.
  54. ↑ Carmi N, Shultz LA, Breaker RR (December 1996). "In vitro selection of self-cleaving DNAs". Chemistry & Biology. 3 (12): 1039–46. doi: 10.1016/s1074-5521(96)90170-2 . PMID   9000012.
  55. ↑ Liu J, Brown AK, Meng X, Cropek DM, Istok JD, Watson DB, Lu Y (February 2007). "A catalytic beacon sensor for uranium with parts-per-trillion sensitivity and millionfold selectivity". Proceedings of the National Academy of Sciences of the United States of America. 104 (7): 2056–61. Bibcode:2007PNAS..104.2056L. doi: 10.1073/pnas.0607875104 . PMC   1892917 . PMID   17284609.
  56. ↑ Torabi SF, Wu P, McGhee CE, Chen L, Hwang K, Zheng N, Cheng J, Lu Y (May 2015). "In vitro selection of a sodium-specific DNAzyme and its application in intracellular sensing". Proceedings of the National Academy of Sciences of the United States of America. 112 (19): 5903–8. Bibcode:2015PNAS..112.5903T. doi: 10.1073/pnas.1420361112 . PMC   4434688 . PMID   25918425.
  57. ↑ Umrao S, Jain V, Chakraborty B, Roy R (August 2018). "Protein-induced fluorescence enhancement as aptamer sensing mechanism for thrombin detection". Sensors and Actuators B: Chemical. 267: 294–301. doi:10.1016/j.snb.2018.04.039. S2CID   103202899.
  58. ↑ Terazono H, Anzai Y, Soloviev M, Yasuda K (April 2010). "Labelling of live cells using fluorescent aptamers: binding reversal with DNA nucleases". Journal of Nanobiotechnology. 8 (1): 8. doi: 10.1186/1477-3155-8-8 . PMC   2861636 . PMID   20388214.
  59. ↑ Mondragón E, Maher LJ (September 2015). "RNA aptamer inhibitors of a restriction endonuclease". Nucleic Acids Research. 43 (15): 7544–55. doi:10.1093/nar/gkv702. PMC   4551934 . PMID   26184872.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.